CleanSlate Centers Plymouth

If you are looking at CleanSlate Centers Plymouth in Wilkes Barre, PA, the basics worth knowing up front: The facility's programming is outpatient (Outpatient, MAT), not residential. This page walks through the questions that tend to matter most to families weighing a specific program.

Care levels at CleanSlate Centers Plymouth

CleanSlate Centers Plymouth is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. The useful move is to have an ASAM-aligned assessment done before admission — ideally by someone outside the facility's admissions team — to confirm that the level of care offered here is what the clinical picture calls for.

Insurance and payment

CleanSlate Centers Plymouth accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. What tends to produce post-admission financial surprise is not the facility being out of network — it is the verbal assurance that did not make it into writing. Ask for the written VOB before admission, save the email, and the rest of the financial conversation becomes a lot simpler.

Before you call

Before admission to CleanSlate Centers Plymouth, three questions consistently produce the most useful information: (1) which ASAM level of care are you treating me at, and what is the clinical rationale; (2) can you send me a written Verification of Benefits for my specific insurance plan; (3) what is your policy on medication-assisted treatment for opioid use disorder — specifically, do you continue patients on buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.